VIR-3434
VIR-3434 is a pharmaceutical drug with 7 clinical trials. Currently 4 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 3 completed trials
Phase Distribution
Phase Distribution
4
Early Stage
3
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
3 of 3 finished
0.0%
0 ended early
4
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection
A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection
SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.
Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434
Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy
Clinical Trials (7)
Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection
A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection
SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.
Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434
Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy
Vaccinal Effect of HBsAg Monoclonal Ab VIR-3434 in Chronic Hepatitis B Infection [VISION]
Study of VIR-3434 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus Infection
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7